Condition

Parkinson's Disease

Compensation

Up to $1600

Duration

12 weeks

Parkinson’s Disease Study II

Official Title

Parkinson's Disease Study II

Study Summary

Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeura™ implant technology where the implant is inserted under the skin. This study will measure how much ropinirole is released in the blood during 3 months of treatment, and evaluate the side effects of this new formulation.

Eligibility and Recruitment Information

Recruitment Status Recruiting
Eligible Genders Both
Eligible Ages 30-80
Inclusion Stable dose of Carbidopa/Levodopa and Ropinirole for at least 30 days.
Exclusion Severe dementia or cognitive impairment
Start Date
Compensation Up to $1600
Location Orlando, FL

Study Information

Condition Parkinson's Disease
Study Phase Phase 2

Administrative Information

Study ID NCT03250117
Investigators Ira J Goodman, MD

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
loading
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.